Srikant Datar - Novartis Non-Executive Independent Director

NVSN Stock  MXN 2,027  0.00  0.00%   

Director

Mr. Srikant M. Datar, Ph.D., has served as NonExecutive Independent Director of Novartis Inc. since 2003. He is Chairman of the Risk Committee, as well as Member of the Audit and Compliance Committee and the Compensation Committee. The Board of Directors has appointed him as Audit Committee Financial Expert. Since 1996, Mr. Datar was the Arthur Lowes Dickinson professor of business administration at Harvard Business School in the United States. Additionally, since 2015, he was faculty chair of the Harvard Innovation Lab and senior associate dean for university affairs at Harvard Business School. He is a member of the boards of directors of ICF International Inc., Stryker Corporationration and TMobile US. He previously served on the boards of HCL Technologies Ltd. and KPIT Cummins Infosystems Ltd, both based in India. Mr. Datar graduated in 1973 with distinction in mathematics and economics from the University of Bombay in India. He is a chartered accountant, and holds two masters degrees and a doctorate from Stanford University. Mr. Datar has worked as an accountant and planner in industry, and as a professor at Carnegie Mellon University, Stanford University and Harvard University, all in the US. His research interests are in the areas of cost management, measurement of productivity, new product development, innovation, timebased competition, incentives and performance evaluation. He is the author of many scientific publications and has received several academic awards and honors. Mr. Datar has also advised and worked with numerous companies in research, development and training. since 2003.
Age 66
Tenure 22 years
Professional MarksMBA
Phone41 61 324 1111
Webhttps://www.novartis.com
Datar is Arthur Lowes Dickinson Professor at the Graduate School of Business Administration at Harvard University. He is also Member of the Board of Directors of ICF International Inc. and of Stryker Corporationrationration, both in the United States, and of KPIT Cummins Infosystems Ltd., India. He graduated with distinction in mathematics and economics from the University of Bombay, India, in 1973. He is a Chartered Accountant and holds two Masters degrees and a Doctor of Philosophy from Stanford University, United States.

Novartis Management Efficiency

The company has return on total asset (ROA) of 0.0645 % which means that it generated a profit of $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1093 %, meaning that it generated $0.1093 on every $100 dollars invested by stockholders. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities.
Novartis AG has accumulated 20.24 B in total debt with debt to equity ratio (D/E) of 0.67, which is about average as compared to similar companies. Novartis AG has a current ratio of 0.88, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Novartis until it has trouble settling it off, either with new capital or with free cash flow. So, Novartis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novartis AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novartis to invest in growth at high rates of return. When we think about Novartis' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 9 records

DIRECTOR Age

Daniel QuintanillaGMxico Transportes SAB
43
Lynn DugleMicron Technology
60
Robert BaileyMicron Technology
61
Mary McCarthyMicron Technology
64
Steven GomoMicron Technology
67
Richard BeyerMicron Technology
71
Patrick ByrneMicron Technology
57
Michael SalvinoDXC Technology
58
Francisco MartinezGMxico Transportes SAB
N/A
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. NOVARTIS operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. It employs 105794 people. Novartis AG (NVSN) is traded on Mexican Exchange in Mexico and employs 102,000 people.

Management Performance

Novartis AG Leadership Team

Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee
Paul Penepent, Head Accounting
Joerg Reinhardt, Independent Non-Executive Chairman of the Board
Ton Buechner, Non-Executive Independent Director
Robert PharmD, Chief Officer
Karen Hale, Chief Officer
Charles Sawyers, Non-Executive Independent Member of the Board
Steven Baert, Chief People & Organization Officer, Member of the Executive Committee
John Tsai, Head of Global Drug Development and Chief Medical Officer, Member of the Executive Committee
Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee
Frans Houten, Non-Executive Independent Director
Nancy Andrews, Non-Executive Independent Director
Daniel Vasella, Honorary Chairman of the Board
Susanne Schaffert, President of Novartis Oncology, Member of the Executive Committee
Enrico Vanni, Lead Independent Non-Executive Vice Chairman of the Board
Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee
Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee
Elizabeth Doherty, Non-Executive Independent Director
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Alex Krauer, Honorary Chairman of the Board
Patrice Bula, Non-Executive Independent Director
Charlotte PamerWieser, Corporate Secretary
Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel
Andreas Planta, Non-Executive Independent Director
William Winters, Non-Executive Independent Member of the Board
Ann Fudge, Non-Executive Independent Director
Srikant Datar, Non-Executive Independent Director
MarieFrance Tschudin, President of Novartis Pharmaceuticals, Member of the Executive Committee
Samir MD, Global Relations
Simon Moroney, Non-Executive Independent Director
James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee
Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
Bridgette Heller, Non-Executive Independent Director

Novartis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novartis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.